Eosinophilic Esophagitis Disease Treatment Market Size, Share, Opportunities, And Trends By Product Type (Off-Label Drugs, Budesonide Oral Suspension, Fluticasone ODT, Mepolizumab, Reslizumab, Benralizumab, Dupilunab, Omalizumab), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), And By Geography - Forecasts From 2025 To 2030

Eosinophilic Esophagitis Disease Treatment Market Size & Forecast:

The eosinophilic esophagitis disease treatment market is projected to grow at a CAGR of 8.15% over the forecast period, increasing from US$504.625 million in 2025 to US$745.096 million by 2030.

Eosinophilic esophagitis (EoE) is a type of allergic inflammatory disease that involves a white blood cell type, eosinophils. Its major symptoms include heartburn, chest pain, and difficulty in swallowing. There are no major medicines that can cure EOE, and multiple foods like shellfish, fish sauce, and oyster sauce can cause it.

Eosinophilic Esophagitis Disease Treatment Market Trends:

The global increase in asthma and allergy cases is estimated to push the global eosinophilic esophagitis disease treatment market forward. The patients suffering from EOE majorly have other conditions like allergic rhinitis, food allergies, or asthma. The Asthma and Allergy Foundation of America, in its report, stated that about 76% of EOE patients have food allergy as a comorbid condition, 70% have Allergic rhinitis, and 51% have asthma. The comorbid condition prevalence of atopic dermatitis and irritable bowel syndrome are 41% and 16%, respectively.

Eosinophilic Esophagitis Disease Treatment Market Restraints:

• Increasing Global Online Pharmacy Market

The online pharmacy market has seen tremendous growth across the globe, mainly due to increased internet penetration, convenience, and increasing adoption of digital healthcare solutions. This expansion has made it easier to access a variety of medications, including specialized treatments, which are particularly useful for managing chronic and rare diseases. As a result, the market for eosinophilic esophagitis (EoE) disease medications is expected to expand significantly because patients are increasingly looking to online channels for their medication needs. In addition, the fact that online pharmacies offer customized drugs, competitive prices, and home delivery contributes to this growth. Furthermore, the growth in telemedicine services complements this trend as it allows for remote consultations and prescriptions, making it easier for EoE patients to get their medications efficiently. This integration of these digital health technologies will further help improve market access and spur growth in the treatment of eosinophilic esophagitis.

The Epharmacy data showed a massive increase in global e-pharmacies visits in 2022, as compared to 2021. The data reveals that in 2022, the total traffic of online pharmacies was 13.6 billion. The Sub-Sahara African region observed a massive increase with a growth of about 98%, followed by 51% growth in the Western Asian region, and 49% growth in the online pharmacies market in the South-Eastern Asia.

Eosinophilic Esophagitis Disease Treatment Market Segment Analysis:

• The Online Pharmacies sector is expected to hold a major market share in the coming years.

The online system allows customers to purchase medications and E-services easily through the online channels. This allows for prompt delivery of the medicines to their homes. This increased demand for online medicine for EoE disease shows upheaval during the COVID-19 pandemic. This gave impetus for the e-pharmacy structure.

The major driver to the surging demand for online medicine is the growing number of people accessing the internet globally; thus, digital health solutions are more accessible than ever. To this effect, internet usage increased from 64% in 2022 to 67% in 2023, according to the International Telecommunication Union's rapid adoption of digital infrastructure. This growth is further driven by advancements in mobile technology, improved internet infrastructure, and higher affordability of smartphones and data plans. Moreover, the ease of accessing online pharmacies, including 24/7 access, competitive pricing, and home delivery services, has also appealed to consumers.

Other crucial reasons for the growing penetration of e-commerce in the pharmaceutical industry include the continued digitization of channels, more intensely penetrating other wider market segments. To consumers, these are increasingly organized and digitally endowed platforms that can reassure quality and authenticity by providing reliable safeguards against counterfeit pharmaceuticals. In relation to chronic and rare conditions like eosinophilic esophagitis, in this direction, access to more targeted medication is critical. Approval by the FDA of Dupixent (dupilumab) in May 2022 as the first treatment approved for adults and children at the age of 12 and older for eosinophilic esophagitis is a significant advance. Online portals where such treatments are available also help them to be accessed with more convenience since patients can conveniently access essential medications without geographical limitations. The combination of digital assurance, convenience, and extended access is what has contributed to the widespread acceptance of e-commerce in the health industry.

Eosinophilic Esophagitis Disease Treatment Market Geographical Outlook:

• The North American region is expected to propel with the highest CAGR in the projected period.

The rising prevalence of this disease in the United States is one of the major reasons for the increased demand for EoE treatment in the coming years.

For instance, the National Organization for Rare Disorders, Inc. (NORD) which published an article in March 2024, on Eosinophilic Esophagitis, stated that standardized to the U.S. population it has been estimated that 56.7 per 1,00,000 people in the US are suffering from eosinophilic esophagitis disease, which makes a total of 1,52,152 cases in total. Additionally, in the past two decades in the U.S., the cases of EoE have almost doubled in both adults and children. Hence, such stats are anticipated to fuel the eosinophilic esophagitis disease treatment market in the coming years.

The rising drug approval for the treatment of this disease of also expected to have a positive impact on the market growth in the coming years. For instance, in January 2024, the Food and Drug Administration (FDA) in the United States approved Dupixent® (dupilumab) for treating EoE for children aged 1 year or older. This approval extends the initial FDA approval for EOE in May 2022 for patients aged 12 years and older and weighing 40 kg. The FDA evaluated Dupixent for this expanded indication under priority review, and this drug proved to have efficiently and safely treated this rare condition. Hence, these product launches are one of the main reasons for market growth in the projected period.

Additionally, the rising healthcare expenditure in the country is anticipated to fuel the market growth in the forecasted period. For instance, according to the U.S. Centers for Medicare & Medicaid Services, and American Medical Services, the per capita healthcare expenditure in 2021 was US$12,914 or US$4.3 billion in total spend in healthcare. This number increased to US$4.5 billion in total healthcare spending, and per capita spending of US$13,493 in 2022. Hence, in the projected period, rising per capita healthcare spending is also expected to positively impact the eosinophilic esophagitis disease treatment market growth. 

Eosinophilic Esophagitis Disease Treatment Market Scope:

Report Metric	Details
Eosinophilic Esophagitis Disease Treatment Market Size in 2025	US$504.625 million
Eosinophilic Esophagitis Disease Treatment Market Size in 2030	US$745.096 million
Growth Rate	CAGR of 8.15%
Study Period	2020 to 2030
Historical Data	2020 to 2023
Base Year	2024
Forecast Period	2025 – 2030
Forecast Unit (Value)	USD Million
Segmentation	Product Type Distribution Channel Geography
Geographical Segmentation	North America, South America, Europe, Middle East and Africa, Asia Pacific
List of Major Companies in Eosinophilic Esophagitis Disease Treatment Market	Ellodi Pharmaceuticals AstraZeneca Plc Bristol-Myers Squibb Co GlaxoSmithKline Plc Sanofi
Customization Scope	Free report customization with purchase

 

Eosinophilic Esophagitis Disease Treatment Market is analyzed into the following segments:

• By Product Type
  • Off-Label Drugs
  • Budesonide Oral Suspension
  • Fluticasone ODT
  • Mepolizumab
  • Reslizumab
  • Benralizumab
  • Dupilunab
  • Omalizumab
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Geography
  • North America
    • USA
    • Canada
    • Mexico
  • South America
    • Brazil
    • Argentina
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Spain
    • Others
  • Middle East and Africa
    • Saudi Arabia
    • UAE
    • Others
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Indonesia
    • Others 

---

1. INTRODUCTION

1.1. Market Overview

1.2. Market Definition

1.3. Scope of the Study

1.4. Market Segmentation

1.5. Currency

1.6. Assumptions

1.7. Base and Forecast Years Timeline

1.8. Key Benefits for the Stakeholders

2. RESEARCH METHODOLOGY  

2.1. Research Design

2.2. Research Process

2.3. Data Validation

3. EXECUTIVE SUMMARY

3.1. Key Findings

3.2. Analyst View

4. MARKET DYNAMICS

4.1. Market Drivers

4.2. Market Restraints

4.3. Porter’s Five Forces Analysis

4.3.1. Bargaining Power of Supplier

4.3.2. Bargaining Power of Buyers

4.3.3. Threat of New Entrants

4.3.4. Threat of Substitutes

4.3.5. Competitive Rivalry in the Industry

4.4. Industry Value Chain Analysis

5. EOSINOPHILIC ESOPHAGITIS DISEASE TREATMENT MARKET BY PRODUCT PIPELINE

6. EOSINOPHILIC ESOPHAGITIS DISEASE TREATMENT MARKET BY PRODUCT TYPE

6.1. Introduction

6.2. Off-Label Drugs 

6.3. Budesonide Oral Suspension

6.4. Fluticasone ODT

6.5. Mepolizumab

6.6. Reslizumab

6.7. Benralizumab

6.8. Dupilumab 

6.9. Omalizumab

7. EOSINOPHILIC ESOPHAGITIS DISEASE TREATMENT MARKET BY DISTRIBUTION CHANNEL

7.1. Introduction

7.2. Hospital Pharmacies

7.3. Retail Pharmacies

7.4. Online Pharmacies

8. EOSINOPHILIC ESOPHAGITIS DISEASE TREATMENT MARKET BY GEOGRAPHY 

8.1. Introduction

8.2. North America

8.2.1. USA

8.2.2. Canada

8.2.3. Mexico

8.3. South America

8.3.1. Brazil

8.3.2. Argentina

8.3.3. Others 

8.4. Europe

8.4.1. Germany 

8.4.2. France

8.4.3. United Kingdom

8.4.4. Spain

8.4.5. Others

8.5. Middle East and Africa

8.5.1. Saudi Arabia

8.5.2. UAE

8.5.3. Others

8.6. Asia Pacific

8.6.1. China 

8.6.2. Japan

8.6.3. India

8.6.4. South Korea

8.6.5. Indonesia

8.6.6. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

9.1. Major Players and Strategy Analysis

9.2. Emerging Players and Market Lucrativeness

9.3. Mergers, Acquisitions, Agreements, and Collaborations

9.4. Competitive Dashboard

10. COMPANY PROFILES

10.1. Ellodi Pharmaceuticals

10.2. AstraZeneca Plc

10.3. Bristol-Myers Squibb Co

10.4. GlaxoSmithKline Plc

10.5. Sanofi

10.6. Takeda Pharmaceutical Company Limited

10.7. Pfizer

10.8. Landos Biopharma, Inc.

10.9. DBV Technologies

10.10. Calypso Biotech

10.11. Revolo Biotherapeutics

10.12. Allakos Inc.

10.13. Regeneron Pharmaceutical

Ellodi Pharmaceuticals

AstraZeneca Plc

Bristol-Myers Squibb Co

GlaxoSmithKline Plc

Sanofi

Takeda Pharmaceutical Company Limited

Pfizer

Landos Biopharma, Inc.

DBV Technologies

Calypso Biotech

Revolo Biotherapeutics

Allakos Inc.

Regeneron Pharmaceutical